Antibody Humanization Market

Antibody Humanization and Affinity Maturation: Services and Platforms, 2017 - 2030

  • Lowest Price Guaranteed From USD 2,499

  • Companies Covered
    115

  • Pages
    224

  • View Count
    9374

Antibody Humanization Market Overview

The global antibody humanization and affinity maturation services market is estimated to grow from $91 million to $127 million by 2030. First discovered in 1975, monoclonal antibodies are considered to be one of the fastest growing therapy segments in the biopharmaceutical industry. In the year 2016, Humira, a monoclonal antibody, generated revenues worth more than USD 16 billion to become the highest selling drug. With a strong development pipeline and high clinical success rate, the market continues to witness increasing adoption of antibody based therapies and products.

The growing industry has faced / continues to face several challenges. One of the biggest hurdles to the growth of antibody based products has been the lack of technical know-how across different stages of drug discovery. This situation is particularly true for the more traditional pharmaceutical companies that have recently ventured into the targeted therapies domain. Some of these companies have mitigated this issue by making specific acquisitions and / or hiring trained personnel to cater to the requirements. However, several others have preferred to out-source these steps to contract services providers. In fact, over the years, a number of services providers offering antibody discovery have been established, and have grown to become an indispensable part of the biopharmaceutical market.

Certain steps of the antibody drug discovery process require advanced expertise, and companies offering these specialized services have attracted significant attention of drug / therapy developers. Two such specific services are to reduce antibody immunogenicity (humanization) and enhance its affinity (affinity maturation). Immunogenicity has continued to be one of the most limiting factors of the clinical success of antibodies. Antibody humanization has emerged as an extensively studied method for reducing antibody immunogenicity. There are several contract services providers that are providing novel technologies beyond the traditional methods to facilitate antibody humanization as well as to enhance antibody affinity. These contract services providers have enabled the drug developers to develop therapeutic antibodies with low immunogenicity and high affinity.

Recent Developments in Antibody Humanization and Affinity Maturation Market:

Several recent developments have taken place in the field of antibody humanization and affinity maturation. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In June 2023, Confo Therapeutics entered into a research agreement with AbCellera for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.

Scope of Report

The “Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030” report provides a comprehensive view on the current landscape and the future outlook of the antibody humanization and affinity maturation contract research services and platforms market. The study presents an in-depth analysis of a diverse set of companies that provide such services across different regions worldwide. In addition to other elements, the report covers the following:

  • The current state of the market with respect to key players along with information on location of these companies, their expertise across antibody humanization and / or affinity maturation, the methodology adopted for providing these services and the revenue / business models used.
  • Elaborate profiles of established / emerging players that have expertise in providing antibody humanization and / or affinity maturation services, highlighting the methodologies adopted by these companies and their recent partnerships and collaborations in the antibody humanization and affinity maturation domain. The profiles also have a detailed future outlook section, detailing the likely strategies that may be adopted by these players to fuel growth in the foreseen future.
  • An analysis of the most active regions in terms of humanization and affinity maturation services for biologics, featuring schematic representations on world maps clearly indicating the location of active services hubs.
  • A benchmark analysis to provide a means to compare existing capabilities within respective peer groups and help stakeholders in the industry to identify ways to achieve a competitive edge over contemporary players.
  • A publication analysis representing recent trends in research on antibody humanization across various academic institutes, highlighting the ongoing innovation in this domain.
  • A SWOT analysis, which elaborates on the strengths, weaknesses, opportunities and threats related to players engaged in this domain.
  • A go-to-guide for outsourcing, representing different models that can be used to facilitate the decision whether companies should out-source a particular activity / operation, or not.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as number of projects being out-sourced, number of projects undertaken per year and expected pricing, we have provided an informed estimate of the likely evolution of the opportunity for antibody humanization and affinity maturation services providers for the period 2017-2030. The base year for the report is 2017. To account for the uncertainties associated with these services and to add robustness to our model, we have provided three forecast scenarios portraying conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These included contributions from Aaron Sato (CSO of LakePharma), Andrew C.R. Martin (Reader in Bioinformatics and Computational Biology at University College London) and Thomas Schirrmann (General Manager of YuMab).

PRICING DETAILS

USD 2,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
click for sending an email to Roots Analysis team sales@rootsanalysis.com